Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Off-target mRNAs with partial seed complementarity represent a significant challenge in the development of RNA interference (RNAi) and antisense therapies. This phenomenon occurs when the seed region of a small interfering RNA (siRNA) or microRNA—typically nucleotides 2 through 8—binds to unintended messenger RNA (mRNA) transcripts that possess complementary sequences, usually in their 3' untranslated regions (UTRs) [Jackson et al., 2003, Nature Biotechnology]. This binding mimics the natural regulatory mechanism of endogenous microRNAs, leading to the degradation or translational repression of these non-target genes [Birmingham et al., 2006, Nature Methods]. Because a single 6-7 nucleotide sequence can appear in hundreds of different mRNAs, a single siRNA can potentially perturb the expression of many genes, leading to unintended biological consequences and potential toxicity [Fedovov et al., 2006, RNA]. Strategies to mitigate these effects include chemical modifications of the siRNA backbone, such as 2'-O-methyl substitutions at position 2 of the guide strand, and the use of bioinformatic algorithms to select sequences with minimal off-target potential [Jackson et al., 2006, RNA]. Understanding and predicting these interactions is crucial for ensuring the safety and specificity of oligonucleotide-based drugs [Burchard et al., 2009, Nature Biotechnology].
Seed-mediated sequence recognition where the 5' end of an siRNA or miRNA guide strand (nucleotides 2-8) binds to partially complementary sequences in the 3' UTR of unintended mRNAs, leading to RISC-mediated degradation or translational repression [Jackson et al., 2003, Nature Biotechnology; Birmingham et al., 2006, Nature Methods].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target messenger RNA with partial seed complementarity (Seed-mediated off-targets).